Lakewood-Amedex Biotherapeutics Secures Composition of Matter Patent Protecting New Bisphosphocin® Compounds Being Developed for High-Need Antimicrobial Infections
Rhea-AI Summary
Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) received a new Australian composition of matter patent for its Bisphosphocin® antimicrobial compounds, covering uses in infections including complicated urinary tract and pulmonary infections.
The patent, issued March 5, 2026, expands a portfolio of 72 granted and 29 pending patents worldwide, supporting development against antimicrobial resistance.
Positive
- New Australian composition of matter patent for Bisphosphocin® compounds issued March 5, 2026
- IP portfolio now totals 72 granted and 29 pending patents globally
- Patent coverage includes complicated urinary tract and pulmonary infections
- Protection spans major regions including US, Europe, China, India, Japan, and Australia
Negative
- None.
News Market Reaction – LABT
In the Jun 22 session, LABT declined 5.46%, reflecting a notable negative market reaction. Argus tracked a peak move of +6.1% during that session. Argus tracked a trough of -23.1% from its starting point during tracking. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility. Trading volume was very high at 4.1x the daily average, suggesting heavy selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 16 | Investor conference | Positive | -0.7% | Upcoming virtual investor forum presentation and Nu-3 Phase 2 development overview. |
| May 27 | IP expansion | Positive | +3.0% | New patents expanding Nu-3 gel and Bisphosphocin platform protection globally. |
| May 18 | Formulation progress | Positive | -36.6% | Positive formulation, stability and manufacturing data enabling planned Phase 2 trial. |
| May 12 | CRO agreement | Positive | +1.9% | PERI engaged as CRO to run Nu-3 Phase 2 clinical program in iDFU. |
| May 01 | AMR data | Positive | +28.9% | Strong antimicrobial resistance profile data for Nu-3 against key resistant pathogens. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
LABT often reacts strongly to positive R&D or IP news, with a mix of aligned rallies and sharp negative divergences.
Key Terms
composition of matter patent regulatory
broad-spectrum antimicrobials medical
antimicrobial resistance medical
intellectual property portfolio financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
New patent enhances global IP footprint and pipeline expansion opportunities
The patent, titled, "Antimicrobial Compounds, Compositions, and Uses Thereof," was issued March 5, 2026, by IP Australia. Lakewood-Amedex Biotherapeutics' intellectual property portfolio is currently comprised of 72 granted patents and 29 pending patents in multiple countries and regions, including
"This newly issued patent adds to our international intellectual property portfolio covering composition of matter patents for the Bisphosphocin® class of compounds," said Kelvin Cooper, Chief Executive Officer of Lakewood-Amedex Biotherapeutics. "Antimicrobial resistance (AMR) is a global crisis that is directly responsible for more than a six million deaths annually. As we work to deliver innovative antimicrobial solutions designed to tackle the challenges of AMR, our substantial IP foundation enhances our ability to bring solutions to the millions of patients in need, while potentially generating value for our shareholders."
About Lakewood-Amedex Biotherapeutics Inc.
Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) is a clinical-stage biotechnology Company developing a novel class of fast-acting, broad-spectrum antimicrobials – the Bisphosphocin® class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. For more information, please visit https://lakewoodamedex.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Lakewood-Amedex Biotherapeutics Inc.'s clinical development plans, regulatory strategy, anticipated trial timing, potential regulatory submissions or approvals, and the potential benefits, safety, efficacy and commercial potential of its Bisphosphocin® platform and product candidates. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially, including risks that clinical trials may not be initiated, completed or successful on expected timelines or at all; preclinical or clinical results may not be predictive of future results; product candidates may not demonstrate safety or efficacy or receive regulatory approval; and risks related to manufacturing, supply, financing and other matters described in the company's SEC filings, including under "Risk Factors." Forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to update them except as required by law.
Contact
Investor Relations
Tiberend Strategic Advisors, Inc.
David Irish
(231) 632-0002
dirish@tiberend.com
Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
646-577-8520
cmcdonald@tiberend.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/lakewood-amedex-biotherapeutics-secures-composition-of-matter-patent-protecting-new-bisphosphocin-compounds-being-developed-for-high-need-antimicrobial-infections-302805728.html
SOURCE Lakewood-Amedex Biotherapeutics Inc.